Cerecor is a biopharmaceutical company that specializes in the development and commercialization of treatments for rare and orphan diseases. With a focus on advancing its clinical-stage pipeline, the company's innovative therapies aim to address unmet patient needs within this space. Cerecor's rare disease pipeline includes promising therapies for inherited metabolic disorders, such as congenital disorders of glycosylation, with the company having received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA. Additionally, Cerecor is working on the development of CERC-002, CERC-006, and CERC-007.